Serpin C and Soluble Fms-like Tyrosine Kinase-1 Levels in Normotensive Pregnant Women May Predict the Development of Preeclampsia

Evaluation of the predictability of estimated levels of Serpin C, sFlt-1 and placental growth factor (PLGF) in blood samples obtained during the 1st trimester from normotensive pregnant women for identification of women liable to develop PE during the course of pregnancy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pre-eclampsia Female Urogenital Diseases and Pregnancy Complications Hypertension, Pregnancy-Induced Pregnancy Complications Urogenital Diseases

Age range

25 year–45 year

Sex eligibility

Female

Study type

Observational

Primary location

Banha University

Banhā, El- Qalyobia, 13511, Egypt

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Normotensive pregnant women had singleton fetus presenting during the 1st trimester
free of exclusion criteria

Exclusion criteria

Age
Sex
Hypertension

Treatment and study plan

ELISA

Diagnostic Test

ELISA estimation of PLGF, sFlt-1 and Serpin C

Primary outcomes

Role of Biomarkers in detection of GHTN

Time frame: 9 months

The predictability of serum biomarkers' levels estimated at enrolment for the development of GHTN.

Sponsors and collaborators

Lead sponsor

Benha University

Other

Registry information

Official study title

Deregulated Serum Levels of Serpin C and Soluble Fms-like Tyrosine Kinase-1 Might Predict the Development of Preeclampsia in Normotensive Pregnant Women

Important dates

Study start: 2023
Primary completion: 2023
Study completion: 2023
First posted: Jan 22, 2024
Registry last updated: Jan 22, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed